Host cell proteins in biotechnology-derived products: A risk assessment framework

Area of Science:

• Biotechnology manufacturing
• Protein therapeutics
• Host cell protein analysis

Background:

• Mammalian and bacterial cells are engineered to produce recombinant therapeutic proteins, such as monoclonal antibodies.
• These host cells naturally synthesize proteins essential for their own survival.
• Biotechnology manufacturing aims for high purity of therapeutic products, but residual host cell proteins (HCPs) can copurify.

Purpose of the Study:

• To enumerate and discuss factors for risk assessment of residual HCPs in drug products.
• To guide decision-making on controlling HCP levels in final therapeutic products.

Main Methods:

• Risk assessment framework for HCPs
• Identification and quantification of residual HCPs
• Evaluation of HCP copurification with therapeutic proteins

Main Results:

• Identification of key factors influencing HCP risk.
• Understanding the potential for HCPs to contaminate therapeutic proteins.
• Establishing a basis for controlling residual HCP levels.

Conclusions:

• A systematic risk assessment is crucial for managing residual HCPs in biopharmaceuticals.
• Controlling HCPs ensures the safety and purity of therapeutic products.
• Informed decision-making based on risk factors optimizes manufacturing processes.